EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon

Nancy Maltez, Lara J Maxwell, Fadumo Rirash, Elizabeth Tanjong Ghogomu, Sarah E Harding, Paul C Tingey, George A Wells, Peter Tugwell, Janet Pope

Cochrane Database of Systematic Reviews · 06.11.2023 · 2025 (2)

DOI: 10.1002/14651858.cd014089 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cochrane Database of Systematic Reviews, online erschienen am 06.11.2023. Verfasst von Nancy Maltez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, The Ottawa Hospital, Ottawa, Canada. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors, Scleroderma, Systemic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 5 InhibitorsScleroderma, SystemicHumansPainSample Size

Substanzen

Phosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Department of Rheumatology, The Ottawa Hospital, Ottawa, Canada.
  • Cochrane Musculoskeletal, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
  • Department of Medicine, University of Western Ontario, London, Canada.
  • Bruyère Research Institute, University of Ottawa, Ottawa, Canada.
  • Pediatric Critical Care Medicine, SUNY Upstate Medical University, Syracuse, USA.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

Zitieren

APA

Maltez, N., Maxwell, L. J., Rirash, F., Tanjong Ghogomu, E., Harding, S. E., Tingey, P. C., Wells, G. A., Tugwell, P., & Pope, J. (2023). Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. Cochrane Database of Systematic Reviews, 2025(2). https://doi.org/10.1002/14651858.cd014089

Vancouver

Maltez N, Maxwell LJ, Rirash F, Tanjong Ghogomu E, Harding SE, Tingey PC, et al. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. Cochrane Database of Systematic Reviews. 2023;2025(2). doi:10.1002/14651858.cd014089

BibTeX
@article{Maltez2023,
  author = {Maltez, Nancy and Maxwell, Lara J and Rirash, Fadumo and Tanjong Ghogomu, Elizabeth and Harding, Sarah E and Tingey, Paul C and Wells, George A and Tugwell, Peter and Pope, Janet},
  title = {Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon},
  journal = {Cochrane Database of Systematic Reviews},
  year = {2023},
  volume = {2025},
  number = {2},
  doi = {10.1002/14651858.cd014089}
}
Kostenlos starten →